SOURCE: Emergent Health Corp.

May 08, 2008 09:15 ET

Emergent Health Corp. (EMGN) Announces Furtherance of Topical Botulinism Patent Pending Formulation for Facial Wrinkles

MYRTLE BEACH, SC--(Marketwire - May 8, 2008) - Emergent Health Corp. (PINKSHEETS: EMGN) announces that its currently licensed patent pending product has cleared the first round of objections by the U.S. Patent and Trademark Office. Emergent believes this topical application of utilizing an ingredient similar to Botox® Cosmetic, which is a registered trademark of Allergan, may be the first step in the painless use of a non-injection treatment that does not require needle penetration. Emergent believes this will open the door for millions to have access to a treatment for facial wrinkles at a lower cost and more readily available. The company will be seeking partners to further develop this concept in a cost effective way.

Emergent is also currently beta testing three websites, Corporate as well as product test site for Hungarest™ Diet Aid ( and Vita-Stim™ Life Enhancement (

Emergent engages in the discovery, development and marketing of products designed to better mankind. Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine defined by the National Institute of Health using nutritionally designed products. Intended products are to be marketed under third party label exemptions. Emergent is focusing current efforts on marketing licensed patent pending natural stem cell propagating agents capable of enhancing each individual's ability to increase their own adult stem cells from their bone marrow. Emergent is also licensed under a patent pending application to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and Professional markets. Research and Development is exploring other areas such as Secretogues that can naturally enhance a person's own Growth Hormone production and similar all natural bioactive formulations to enhance human performance safely, ethically, legally and utilizing known body mechanisms without the use of drugs. Emergent does not claim any of its products diagnose, treat, cure or prevent any disease. Emergent was founded in 2006 and headquartered in Myrtle Beach, SC.

This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.

This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.

Contact Information

  • For Investor Relations:
    Investor Development Group, LLC
    Robert Adams